This article was originally published in The Gray Sheet
Executive SummarySecondary offering net proceeds increase to $15.5 mil. following the exercise of a 300,000-share overallotment option, including 75,000 shares from a selling shareholder. All together, the deal included 2.3 mil. shares at $10 each, 1.7 mil. shares offered by the company and 575,000 offered by selling shareholders. Lehman Brothers, Bear Stearns, and Adams Harkness & Hill were managers. Thoratec plans to commence patient enrollment within the next three months for the U.S. Alternative Graft Investigational Study (AEGIS) trial of its Aria coronary artery bypass graft. FDA approval of an investigational device exemption was announced May 11
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.